Citadel Advisors
MYOV

Citadel Advisors’s Myovant Sciences Ltd. MYOV Stock Holding History

Citadel Advisors’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33,900
Closed -$914K – 16062
2022
Q4 		$914K Sell
33,900
-108,700
-76% -$2.86M ﹤0.01% 6981
2022
Q3 		$2.56M Buy
142,600
+72,300
+103% +$1.15M ﹤0.01% 5114
2022
Q2 		$874K Sell
70,300
-23,600
-25% -$260K ﹤0.01% 7333
2022
Q1 		$1.25M Sell
93,900
-138,000
-60% -$1.85M ﹤0.01% 7196
2021
Q4 		$3.61M Sell
231,900
-38,400
-14% -$733K ﹤0.01% 4963
2021
Q3 		$6.07M Buy
270,300
+28,800
+12% +$632K ﹤0.01% 3941
2021
Q2 		$5.5M Sell
241,500
-5,200
-2% -$109K ﹤0.01% 4228
2021
Q1 		$5.08M Buy
246,700
+46,500
+23% +$1.06M ﹤0.01% 4227
2020
Q4 		$5.53M Buy
200,200
+75,800
+61% +$1.48M ﹤0.01% 3521
2020
Q3 		$1.75M Buy
124,400
+10,100
+9% +$188K ﹤0.01% 4983
2020
Q2 		$2.36M Sell
114,300
-25,100
-18% -$341K ﹤0.01% 4290
2020
Q1 		$1.05M Sell
139,400
-11,700
-8% -$131K ﹤0.01% 5248
2019
Q4 		$2.35M Buy
+151,100
New +$1.52M ﹤0.01% 4151

Other funds holding MYOV

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's MYOV Position: Q1 2023 in Review

Citadel Advisors sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 100,059 shares — an estimated $2.7M sold.

Citadel Advisors first reported a position in MYOV in Q2 2019 and held it in 15 quarters. The position peaked at $17.4M in Q3 2022. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

  • Citadel Advisors reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 100,059 Myovant Sciences Ltd. shares in Q1 2023, an estimated $2.7M.
  • Citadel Advisors first reported a position in Myovant Sciences Ltd. in Q2 2019 and held it in 15 quarters.
  • Citadel Advisors's Myovant Sciences Ltd. position peaked at $17.4M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.